Cartalax
PH-CART-001
Specifications
- Purity (HPLC)
- ≥99%
- Size
- 20mg
- Molecular Weight
- 333.29 Da
- Catalog No.
- PH-CART-001
Description
Cartalax (AED) is a synthetic tripeptide bioregulator with the sequence Ala-Glu-Asp, also referenced in the literature as the T-31 peptide. It belongs to the Khavinson family of short peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and has been studied for its role in cartilage and connective-tissue homeostasis during cellular aging.
Mechanism of Action
As a short peptide bioregulator, Cartalax is proposed to penetrate cells and modulate gene expression linked to the senescence-associated secretory phenotype (SASP) of chondrocytes. In vitro, the AED peptide normalized synthesis of the pro-apoptotic proteins p16, p21 and p53 and the pro-inflammatory cytokines TNF-alpha and IL-1alpha while restoring Sirt1 expression, an effect associated with its geroprotective activity in osteoarthritis models (Myakisheva et al., 2023).
Research Applications
- Chondrocyte aging and osteoarthritis models (Myakisheva et al., 2023)
- Modulation of aging-related gene expression in mesenchymal stem cells (Ashapkin et al., 2020)
- Skin fibroblast aging and apoptosis studies (Linkova et al., 2016)
- Neuronal differentiation of stem cells (Caputi et al., 2019)
Product Specifications
- Purity: >=99% (HPLC verified)
- Molecular Weight: 333.29 Da
- Molecular Formula: C12H19N3O8
- Sequence: Ala-Glu-Asp (AED)
- Form: Lyophilized powder
- Storage: -20C, protected from light
References
- Myakisheva SN, et al. Adv Gerontol. 2023;36(2):234-238. PMID: 37356100
- Ashapkin V, et al. Mol Biol Rep. 2020;47(6):4323-4329. DOI: 10.1007/s11033-020-05506-3
- Linkova NS, et al. Bull Exp Biol Med. 2016;161(1):175-178. DOI: 10.1007/s10517-016-3370-x
- Caputi S, et al. Int J Immunopathol Pharmacol. 2019;33. DOI: 10.1177/2058738419828613
For research use only. Not for human consumption.
Verification
Storage & Handling
Storage
Cartalax is supplied as a lyophilized powder. Keep it sealed, dry, and away from light until reconstitution.
Reconstitution
Let the vial reach room temperature before opening, then add solvent slowly down the vial wall — do not shake.
Stability
Lyophilized material is stable when frozen. Once reconstituted, keep it cold and minimise handling to preserve integrity.
Research Overview
Cartalax is a synthetic peptide compound used in laboratory research settings. Researchers studying longevity and cellular aging research use this compound to investigate cellular signaling pathways, receptor binding affinities, and structure-activity relationships. Each batch is manufactured under controlled conditions and verified through HPLC and mass spectrometry analysis to ensure consistency across experimental replicates.
Documentation & Resources
- Certificate of Analysis for Cartalax — batch-specific purity and identity verification
- Research Blog — protocols, guides, and peptide research literature
- Research Use Policy — handling and compliance guidelines
Frequently Asked Questions
What purity is Cartalax?
Each lot of Cartalax is verified to ≥99% by HPLC and confirmed by mass spectrometry. Results are documented in a batch-specific Certificate of Analysis.
Does Cartalax include a Certificate of Analysis?
Yes. A batch-specific Certificate of Analysis for Cartalax documents its purity and identity and is available on our COA page.
How should Cartalax be stored?
Cartalax is supplied as a lyophilized powder. For short-term storage keep it refrigerated; for long-term storage keep it frozen, away from light and moisture.
How is Cartalax shipped?
Orders ship at a $15 flat rate, free on orders over $199, in discreet, insulated packaging. Domestic delivery typically takes 1–3 business days.
Can Cartalax be used on humans or animals?
No. Cartalax is supplied strictly for in-vitro laboratory research. It is not for human or veterinary use, consumption, or diagnostic or clinical applications.
